U-UCBJY

Q:UCBJY - UCB S.A. UNSP ADR EACH REPR 0.5 ORD - Website unknown - click to update

19:23:35 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
UCBJY - Q	not subscribed					45.471	+0.501	1.1	6.2	278	108	45.67 45.70 45.4255	63.94 32.82	15:51:33	Mar 18	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTC Pink Limited -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - Last 10 of 108

More trades...

Time ET	Ex	Price	Change	Volume
15:51:33	Q	45.52	0.55	81
15:49:59	Q	45.47	0.50	2
15:49:13	Q	45.52	0.55	70
15:46:16	Q	45.471	0.501	563
15:45:35	Q	45.45	0.48	8
15:45:35	Q	45.52	0.55	50
15:45:15	Q	45.485	0.515	1
15:45:10	Q	45.485	0.515	7
15:45:08	Q	45.485	0.515	110
15:45:05	Q	45.485	0.515	11

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-03-18 14:10	U:UCBJY	News Release200	Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
2023-03-16 07:00	U:UCBJY	News Release200	UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa

Date ET

Symbol

Type

Headline

2023-03-18 14:10

U:UCBJY

News Release

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

2023-03-16 07:00

U:UCBJY

News Release

UCB to Present Eight Bimekizumab Abstracts at AAD 2023 with Results from Studies in Psoriasis, Psoriatic Arthritis, and Hidradenitis Suppurativa